Microsoft and UiPath have announced a partnership in enterprise automation with the launch of integration between Microsoft Copilot Studio and UiPath Studio.

Mizuho lowered the firm’s price target on UiPath (PATH) to $11 from $12 and keeps a Neutral rating on the shares as part of a Q1 preview for ...

UiPath (PATH) closed the most recent trading day at $10.71, moving -1.47% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.79%. Elsewhere, the Dow ...

Despite a 20% stock decline, we maintain a bullish view on UiPath due to its strategic pivot to Agentic AI and strong ...

Confluent, Inc. (Nasdaq:CFLT), the data streaming pioneer, today announced the promotion of Ryan Mac Ban to Chief Revenue ...

Investors following Cathie Wood’s ARK ETFs can observe a dynamic approach to portfolio management, with the firm actively buying and selling positions based on their evolving investment thesis. The ...

A new medical summarization AI agent will help healthcare organizations reduce overall prior authorization turn-around time ...

Learn more about whether Asana, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare ...

UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.